RiverPark Advisors LLC cut its position in shares of Core Laboratories N.V. (NYSE:CLB) by 46.8% during the second quarter, Holdings Channel reports. The firm owned 315,000 shares of the oil and gas company’s stock after selling 277,500 shares during the period. Core Laboratories N.V. comprises 3.6% of RiverPark Advisors LLC’s holdings, making the stock its 12th largest position. RiverPark Advisors LLC’s holdings in Core Laboratories N.V. were worth $31,900,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its position in Core Laboratories N.V. by 42.7% in the first quarter. Janney Montgomery Scott LLC now owns 11,367 shares of the oil and gas company’s stock worth $1,313,000 after buying an additional 3,404 shares during the period. B & T Capital Management DBA Alpha Capital Management raised its position in Core Laboratories N.V. by 42.7% in the first quarter. B & T Capital Management DBA Alpha Capital Management now owns 14,371 shares of the oil and gas company’s stock worth $1,660,000 after buying an additional 4,303 shares during the period. ProShare Advisors LLC raised its position in Core Laboratories N.V. by 8.5% in the first quarter. ProShare Advisors LLC now owns 3,802 shares of the oil and gas company’s stock worth $439,000 after buying an additional 297 shares during the period. BTR Capital Management Inc. raised its position in Core Laboratories N.V. by 19.7% in the first quarter. BTR Capital Management Inc. now owns 9,675 shares of the oil and gas company’s stock worth $1,118,000 after buying an additional 1,595 shares during the period. Finally, BTIM Corp. raised its position in Core Laboratories N.V. by 6.3% in the first quarter. BTIM Corp. now owns 77,224 shares of the oil and gas company’s stock worth $8,921,000 after buying an additional 4,544 shares during the period.

Shares of Core Laboratories N.V. (NYSE CLB) opened at 91.67 on Tuesday. The firm has a 50-day moving average of $101.27 and a 200 day moving average of $108.43. Core Laboratories N.V. has a 12 month low of $91.64 and a 12 month high of $125.83. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 56.24 and a beta of 1.60.

Core Laboratories N.V. (NYSE:CLB) last announced its quarterly earnings data on Monday, July 24th. The oil and gas company reported $0.52 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.51 by $0.01. Core Laboratories N.V. had a net margin of 11.80% and a return on equity of 49.29%. The company had revenue of $163.90 million for the quarter, compared to the consensus estimate of $168.23 million. During the same period in the prior year, the firm posted $0.35 EPS. Core Laboratories N.V.’s revenue for the quarter was up 10.7% on a year-over-year basis. On average, analysts expect that Core Laboratories N.V. will post $2.09 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 14th. Investors of record on Monday, July 17th were given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 2.40%. The ex-dividend date was Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio (DPR) is 134.15%.

TRADEMARK VIOLATION NOTICE: “RiverPark Advisors LLC Reduces Stake in Core Laboratories N.V. (CLB)” was published by Watch List News and is owned by of Watch List News. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The correct version of this report can be accessed at https://www.watchlistnews.com/riverpark-advisors-llc-reduces-stake-in-core-laboratories-n-v-clb/1491360.html.

A number of research analysts have weighed in on the stock. ABN Amro raised shares of Core Laboratories N.V. to a “hold” rating in a research note on Friday, April 21st. Zacks Investment Research raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Friday, April 21st. Loop Capital raised shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and raised their price objective for the company from $125.00 to $130.00 in a research note on Friday, April 21st. Scotiabank set a $136.00 price objective on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research note on Saturday, April 22nd. Finally, BidaskClub raised shares of Core Laboratories N.V. from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Three research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus price target of $117.17.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.